Skip to the main content

Review article

https://doi.org/10.20471/LO.2023.51.01.04

Latest perspectives on the benefits of neoadjuvant therapy for patients with advanced gastric cancer

Tea Budija orcid id orcid.org/0009-0008-9072-2213 ; School of Medicine, University of Zagreb, Zagreb, Croatia
Jasmina Marić-Brozić orcid id orcid.org/0000-0002-5978-5960 ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia and School of Medicine, University of Zagreb, Zagreb, Croatia


Full text: english pdf 503 Kb

page 25-30

downloads: 148

cite


Abstract

Treatment for gastric cancer has multiple approaches and options across the world. Standard treatment for the Asian population comprises D2-gastrectomy and adjuvant chemotherapy. However, in Europe and North America, clinical trials have shown that perioperative chemotherapy, given to patients before surgery, could improve resection and survival rates significantly. Most recent studies have also discussed the advantages of doublet vs. triplet chemotherapy regimens. Furthermore, researchers have been comparing the effects of perioperative chemoradiotherapy as opposed to chemotherapy alone. The specific advantages of previously stated therapy options, as well as any novel treatments, should be researched more thoroughly in the future.

Keywords

gastric cancer; screening; neoadjuvant therapy; docetaxel

Hrčak ID:

305507

URI

https://hrcak.srce.hr/305507

Publication date:

27.5.2023.

Article data in other languages: croatian

Visits: 495 *